Genetic changes in nonepithelial ovarian cancer

Expert Review of Anticancer Therapy

Volumn 13, Issue 7, 2013, Pages 871-882

  Van Nieuwenhuysen, Els ^a   Lambrechts, Sandrina ^a   Lambrechts, Diether ^b   Leunen, Karin ^a   Amant, Frédéric ^a,c   Vergote, Ignace ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

Author keywords

germ cell tumor; granulosa cell; miRNA; mutation; ovary; sex cord stromal tumor; targeted therapy; testicular germ cell tumor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANASTROZOLE; ANTINEOPLASTIC AGENT; BETA CATENIN; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN; BORTEZOMIB; BUPARLISIB; CEDIRANIB; CETUXIMAB; ERLOTINIB; FOLLITROPIN RECEPTOR; IMATINIB; LAPATINIB; LETROZOLE; MATUZUMAB; MESSENGER RNA; NINTEDANIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SF 11226; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN; XL 147;

ANDROBLASTOMA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL FUNCTION; CHROMOSOME ABERRATION; DRUG DESIGN; DYSGERMINOMA; FOXL2 GENE; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GERM CELL TUMOR; GRANULOSA CELL; GYNECOLOGIC CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; NONEPITHELIAL OVARIAN CANCER; NONHUMAN; ONSET AGE; OVARY CANCER; OVARY CARCINOMA; PRIMORDIAL GERM CELL; REVIEW; SEX CORD TUMOR; SEX DETERMINATION; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GENE; Y CHROMOSOME; YOLK SAC TUMOR;

EID: 84880814592     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.811174     Document Type: Review

References (97)

1. Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr. Rev. 33(1), 109-144 (2012
2. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat. Rev. 34(5), 427-441 (2008
3. Despierre E, Lambrechts D, Neven P, Amant F, Lambrechts S, Vergote I. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol. Oncol. 117(2), 358-365 (2010
4. Integrated genomic analyses of ovarian cancer. Cancer Genome Atlas Research Network. Nature 474(7353), 609-615 (2011
5. Bast RC Jr. Molecular approaches to personalizing management of ovarian cancer. Ann. Oncol. 22(Suppl. 8), viii5-Viii15 (2011
6. Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res. 72(11), 2701-2704 (2012
7. Gershenson DM. Treatment of ovarian cancer in young women. Clin. Obstet. Gynecol. 55(1), 65-74 (2012
8. Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian stromal cell tumors. J. Clin. Oncol. 25(20), 2944-2951 (2007
9. Lin YS, Eng HL, Jan YJ et al. Molecular cytogenetics of ovarian granulosa cell tumors by comparative genomic hybridization. Gynecol. Oncol. 97(1), 68-73 (2005
10. Fuller PJ, Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol. Metab. 15(3), 122-128 (2004
11. Shah SP, Köbel M, Senz J et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 360(26), 2719-2729 (2009
12. Jamieson S, Butzow R, Andersson N et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod. Pathol. 23(11), 1477-1485 (2010
13. Kim MS, Hur SY, Yoo NJ, Lee SH. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and human cancers. J. Pathol. 221, 174-152 (2010
14. Al-Agha OM, Huwait HF, Chow C et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am. J. Surg. Pathol. 35(4), 484-494 (2011
15. Gershon R, Aviel-Ronen S, Korach J et al. FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. Gynecol. Oncol. 122(3), 580-584 (2011
16. Uda M, Ottolenghi C, Crisponi L et al. Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. Hum. Mol. Genet. 13(11), 1171-1181 (2004
17. Crisponi L, Deiana M, Loi A et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ ptosis/epicanthus inversus syndrome. Nat. Genet. 27(2), 159-166 (2001
18. Uhlenhaut NH, Jakob S, Anlag K et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell 139(6), 1130-1142 (2009
19. Rosario R, Araki H, Print CG, Shelling AN. The transcriptional targets of mutant FOXL2 in granulosa cell tumours. PLoS ONE 7(9), e46270 (2012
20. Benayoun BA, Anttonen M, Lhôte D et al. Adult ovarian granulosa cell tumor transcriptomics: Prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation. Oncogene doi:10.1038/onc.2012.298 (2012) (Epub ahead of print
21. Fleming NI, Knower KC, Lazarus KA, Fuller PJ, Simpson ER, Clyne CD. Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. PLoS ONE 5(12), e14389 (2010
22. Kim JH, Yoon S, Park M et al. Differential apoptotic activities of wild-Type FOXL2 and the adult-Type granulosa cell tumorassociated mutant FOXL2 (C134W). Oncogene 30(14), 1653-1663 (2011
23. Bilandzic M, Chu S, Wang Y et al. Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells. Mol. Endocrinol. 27(3), 466-479 (2013
24. Gartel LA. A new target for proteasome inhibitors: FOXM1. Expert Opin. Investig. Drugs 19(2), 235-242 (2010
25. Yang JY, Hung MC. Deciphering the role of forkhead transcription factors in cancer therapy. Curr. Drug Targets 12(9), 1284-1290 (2011
26. Kotlar TJ, Young RH, Albanese C, Crowley WF Jr, Scully RE, Jameson JL. A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. J. Clin. Endocrinol. Metab. 82(4), 1020-1026 (1997
27. Hussein S, Chu S, Fuller PJ. Comment on analysis of mutations in genes of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. J. Clin. Endocrinol. Metab. 84(10), 3852 (1999
28. Hannon TS, King DW, Brinkman AD et al. Premature thelarche and granulosa cell tumors: A search for FSH receptor and G5α activating mutations. J. Pediatr. Endocrinol. Metab. 15(Suppl. 3), 891-895 (2002
29. Kotlar T, Young RH, Albanese C, Crowley WF Jr, Scully RE, Jameson JL. Absence of mutations in the FSH receptor in ovarian granulosa cell tumors. J. Clin. Endocrinol. Metab. 83(8), 3001 (1998
30. Kalfa N, Ecochard A, Patte C et al. Activating mutations of the stimulatory g protein in juvenile ovarian granulosa cell tumors: A new prognostic factor̈ J. Clin. Endocrinol. Metab. 91(5), 1842-1847 (2006
31. Gonzalez-Robayna IJ, Falender AE, Ochsner S, Firestone GL, Richards JS. Follicle-Stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-induced kinase (Sgk): Evidence for A kinase-independent signaling by FSH in granulosa cells. Mol. Endocrinol. 14(8), 1283-1300 (2000
32. Bittinger S, Alexiadis M, Fuller PJ. Expression status and mutational analysis of the PTEN and P13K subunit genes in ovarian granulosa cell tumors. Int. J. Gynecol. Cancer 19(3), 339-342 (2009
33. Brachmann SM, Kleylein-Sohn J, Gaulis S et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol. Cancer Ther. 11(8), 1747-1757 (2012
34. Chappell WH, Steelman LS, Long JM et al. Ras/Raf/MEK/ERK and PI3K/ PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health. Oncotarget 2(3), 135-164 (2011
35. Shapiro G, Kwak E, Baselga J et al. Phase I dose-escalation study of XL-147, a PI3K inhibitor administered orally to patients with solid tumors. J. Clin. Oncol. 27(Suppl.), Abstract 3500 (2009
36. Yap TA, Yan L, Patnaik A et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29(35), 4688-4695 (2011
37. Slomovitz BM, Lu KH, Johnston T et al. A Phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116(23), 5415-5419 (2010
38. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest. New Drugs 31(1), 213-229 (2013
39. Leibl S, Bodo K, Gogg-Kammerer M et al. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. Gynecol. Oncol. 101(1), 18-23 (2006
40. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell. Signal. 19(10), 2013-2023 (2007
41. Furger C, Fiddes RJ, Quinn DI, Bova RJ, Daly RJ, Sutherland RL. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-β2/PE40. Cancer Res. 58(9), 1773-1778 (1998
42. Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int. J. Clin. Oncol. 17(5), 430-440 (2012
43. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the RAS-mitogen-Activated protein kinase pathway. Clin. Cancer Res. 14(12), 3651-3656 (2008
44. Matei D, Sill MW, Lankes HA et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial. J. Clin. Oncol. 29(1), 69-75 (2011
45. Carracedo A, Pandolfi PP. The PTENPI3K pathway: Of feedbacks and crosstalks. Oncogene 27(41), 5527-5541 (2008
46. Färkkilä A, Anttonen M, Pociuviene J et al. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. Eur. J. Endocrinol. 164(1), 115-122 (2011
47. Tao X, Sood AK, Deavers MT et al. Anti-Angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol. Oncol. 114(3), 431-436 (2009
48. Kesterson JP, Mhawech-Fauceglia P, Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: A case report. Gynecol. Oncol. 111(3), 527-529 (2008
49. Barrena Medel NI, Herzog TJ, Wright JD, Lewin SN. Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: A case report. Anticancer Res. 30(11), 4767-4768 (2010
50. Manchana T, Ittiwut C, Mutirangura A, Kavanagh JJ. Targeted therapies for rare gynaecological cancers. Lancet Oncol. 11(7), 685-693 (2010
51. Knight PG, Glister C. TGF-β superfamily members and ovarian follicle development. Reproduction 132(2), 191-206 (2006
52. Lappöhn RE, Burger HG, Bouma J, Bangah M, Krans M, de Bruijn HW. Inhibin as a marker for granulosa-cell tumors. N. Engl. J. Med. 321(12), 790-793 (1989
53. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. α-Inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360(6402), 313-319 (1992
54. de Caestecker M. The transforming growth factor-β superfamily of receptors. Cytokine Growth Factor Rev. 15(1), 1-11 (2004
55. Fuller PJ, Chu S, Jobling T, Mamers P, Healy DL, Burger HG. Inhibin subunit gene expression in ovarian cancer. Gynecol. Oncol. 73(2), 273-279 (1999
56. Bilandzic M, Chu S, Farnworth PG et al. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol. Endocrinol. 23(4), 539-548 (2009
57. Pangas SA. Bone morphogenetic protein signaling transcription factor (SMAD) function in granulosa cells. Mol. Cell. Endocrinol. 356(1-2), 40-47 (2012
58. Alexiadis M, Eriksson N, Jamieson S et al. Nuclear receptor profiling of ovarian granulosa cell tumors. Horm. Cancer 2(3), 157-169 (2011
59. Briasoulis E, Karavasilis V, Pavlidis N. Megestrol activity in recurrent adult type granulosa cell tumour of the ovary. Ann. Oncol. 8(8), 811-812 (1997
60. Hardy RD, Bell JG, Nicely CJ, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: Case report and review of the literature. Gynecol. Oncol. 96(3), 865-869 (2005
61. Fishman A, Kudelka AP, Tresukosol D et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J. Reprod. Med. 41(6), 393-396 (1996
62. Ameryckx L, Fatemi HM, De Sutter P, Amy JJ. GnRH antagonist in the adjuvant treatment of a recurrent ovarian granulosa cell tumor: A case report. Gynecol. Oncol. 99(3), 764-766 (2005
63. Sjoquist KM, Martyn J, Edmondson RJ, Friedlander ML. The role of hormonal therapy in gynecological cancers-current status and future directions. Int. J. Gynecol. Cancer 21(7), 1328-1333 (2011
64. Freeman SA, Modesitt SC. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: A report of 2 cases. Gynecol. Oncol. 103(2), 755-758 (2006
65. Korach J, Perri T, Beiner M, Davidzon T, Fridman E, Ben-Baruch G. Promising effect of aromatase inhibitors on recurrent granulosa cell tumors. Int. J. Gynecol. Cancer 19(5), 830-833 (2009
66. Alhilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: Brief report and review of the literature. J. Obstet. Gynaecol. Res. 38(1), 340-344 (2012
67. Chu S, Nishi Y, Yanase T, Nawata H, Fuller PJ. Transrepression of estrogen receptor β signaling by nuclear factor-κB in ovarian granulosa cells. Mol. Endocrinol. 18(8), 1919-1928 (2004
68. Chu S, Alexiadis M, Fuller PJ. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors. Reprod. Sci. 16(4), 397-407 (2009
69. Kalfa N, Philibert P, Patte C et al. Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children. Fertil. Steril. 87(4), 896-901 (2007
70. Lyons J, Landis CA, Harsh G et al. Two G protein oncogenes in human endocrine tumors. Science 249(4969), 655-659 (1990
71. Olivier P, Simoneau-Roy J, Francoeur D et al. Leydig cell tumors in children: Contrasting clinical, hormonal, anatomical, and molecular characteristics in boys and girls. J. Pediatr. 161(6), 1147-1152 (2012
72. Heravi-Moussavi A, Anglesio MS, Cheng SW et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N. Engl. J. Med. 366(3), 234-242 (2012
73. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol. Cancer 6, 12 (2007
74. Sever M, Jones TD, Roth LM et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: Diagnostic and therapeutic implications. Mod. Pathol. 18(11), 1411-1416 (2005
75. Despierre E, Lambrechts S, Leunen K et al. Folate receptor α: Potential therapeutic target for pure yolk sac tumors and mixed germ cell tumors with yolk sac component. Abstract IGCS (2012
76. Jelovac D, Armstrong DK. Role of farletuzumab in epithelial ovarian carcinoma. Curr. Pharm. Des. 18(25), 3812-3815 (2012
77. Kraggerud SM, Szymanska J, Abeler VM et al. DNA copy number changes in malignant ovarian germ cell tumors. Cancer Res. 60(11), 3025-3030 (2000
78. Cossu-Rocca P, Zhang S, Roth LM et al. Chromosome 12p abnormalities in dysgerminoma of the ovary: A FISH analysis. Mod. Pathol. 19(4), 611-615 (2006
79. Cheng L, Roth LM, Zhang S et al. KIT gene mutation and amplification in dysgerminoma of the ovary. Cancer 117(10), 2096-2103 (2011
80. Crockford GP, Linger R, Hockley S et al. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum. Mol. Genet. 15(3), 443-451 (2006
81. Giambartolomei C, Mueller CM, Greene MH, Korde LA. A mini-review of familial ovarian germ cell tumors: An additional manifestation of the familial testicular germ cell tumor syndrome. Cancer Epidemiol. 33(1), 31-36 (2009
82. Rapley EA, Turnbull C, Al Olama AA et al.; UK Testicular Cancer Collaboration. A genome-wide association study of testicular germ cell tumor. Nat. Genet. 41(7), 807-810 (2009
83. Fritsch MK, Schneider DT, Schuster AE, Murdoch FE, Perlman EJ. Activation of Wnt/β-catenin signaling in distinct histologic subtypes of human germ cell tumors. Pediatr. Dev. Pathol. 9(2), 115-131 (2006
84. Fustino N, Rakheja D, Ateek CS, Neumann JC, Amatruda JF. Bone morphogenetic protein signalling activity distinguishes histological subsets of paediatric germ cell tumours. Int. J. Androl. 34(4 Pt 2), e218-e233 (2011
85. Vergote I, Dieleman V, Becquart D, Buytaert P. Dysgerminoma of the ovary in association with XY gonadal dysgenesis. Eur. J. Obstet. Gynecol. Reprod. Biol. 14(6), 385-391 (1983
86. Turnbull C, Rapley EA, Seal S et al.; UK Testicular Cancer Collaboration. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat. Genet. 42(7), 604-607 (2010
87. Schumacher FR, Wang Z, Skotheim RI et al. Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum. Mol. Genet. 22(13), 2748-2753 (2013
88. Poynter JN, Hooten AJ, Frazier AL, Ross JA. Associations between variants in KITLG, SPRY4, BAK1, and DMRT1 and pediatric germ cell tumors. Genes. Chromosomes Cancer 51(3), 266-271 (2012
89. Palmer RD, Murray MJ, Saini HK et al.; Childrens Cancer and Leukaemia Group. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 70(7), 2911-2923 (2010
90. Farley J, Brady WE, Vathipadiekal V et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-Label, single-Arm, Phase 2 study. Lancet Oncol. 14(2), 134-140 (2013
91. Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol. 27(33), 5601-5606 (2009
92. Biagi JJ, Oza AM, Chalchal HI et al. A Phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study. Ann. Oncol. 22(2), 335-340 (2011
93. Friedlander M, Hancock KC, Rischin D et al. A Phase II, open-Label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol. Oncol. 119(1), 32-37 (2010
94. Ledermann JA, Hackshaw A, Kaye S et al. Randomized Phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J. Clin. Oncol. 29(28), 3798-3804 (2011
95. Karlan BY, Oza AM, Richardson GE et al. Randomized, double-blind, placebo-controlled Phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J. Clin. Oncol. 30(4), 362-371 (2012
96. Aghajanian C, Blessing JA, Darcy KM et al.; Gynecologic Oncology Group. A Phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol. Oncol. 115(2), 215-220 (2009
97. Schilder RJ, Sill MW, Lee RB et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group Study. J. Clin. Oncol. 26(20), 3418-3425 (2008